F. Cougnon et al. / Tetrahedron 63 (2007) 11959–11964
11963
1
55%). H NMR (CDCl3, 300 MHz): d 0.71 (d, 3H, J¼6.8),
hydrazino)-butyric acid methyl ester (12b). Treating
10 (0.157 mmol, 40 mg) according to method A (ZnEt2,
1.5 equiv) in the presence of 2a (0.787 mmol, 195 mg) led
after purification on silica gel (0–100% AcOEt/pentane) to
12a (32.6 mg, 0.109 mmol, 70%).
0.93 (d, 3H, J¼6.8), 1.89 (oct, 1H, J¼6.9), 2.32 (s, 3H),
3.73 (s, 3H), 3.96 (t, 1H, J¼7.9), 5.12 (d, 1H, J¼8.1), 6.62
(d, 2H, J¼8.8), 6.84 (d, 2H, J¼8.8), 7.06 (d, 2H, J¼8.3),
7.48 (d, 2H, J¼8.3). 13C NMR (CDCl3, 75 MHz): d 19.0
(CH3), 19.2 (CH3), 21.4 (CH3), 34.4 (CH), 55.2 (CH3),
63.7 (CH), 113.4 (CH), 127.0 (CH), 128.0 (CH), 129.1
(CH), 132.1 (C), 137.7 (C), 142.6 (C), 158.6 (C). Anal. Calcd
for C18NSO3H23: C, 64.84; N, 4.20; S, 9.61; H, 6.95. Found:
C, 64.78; N, 4.17; S, 9.25; H, 7.25.
Treating 10 (0.157 mmol, 40 mg) according to method A
(ZnEt2, 1.5 equiv) in the presence of 2a (0.654 mmol,
162 mg) led after purification on silica gel (0–100%
AcOEt/pentane) to 12a (34.3 mg, 0.115 mmol, 73%) and
12b (2.5 mg, 0.009 mmol, 6%).
4.2.6. 4-[2-Methyl-1-(toluene-4-sulfonylamino)-propyl]-
benzoic acid methyl ester (8a). Treating 5 (0.157 mmol,
50 mg) according to method A in the presence of 2a
(0.788 mmol, 195 mg) led after purification on silica gel
(0–100% AcOEt/pentane) to 8a (45 mg, 0.124 mmol,
79%). 1H NMR (CDCl3, 300 MHz): d 0.73 (d, 3H, J¼6.8),
0.94 (d, 3H, J¼6.8), 1.94 (oct, 1H, J¼6.9), 2.31 (s, 3H),
3.90 (s, 3H), 4.09 (dd, 1H, J¼7.7 and 7.9), 5.63 (d, 1H,
J¼8.5), 7.05 (d, 4H, J¼8.1), 7.50 (d, 2H, J¼8.3), 7.78 (d,
2H, J¼8.3). 13C NMR (CDCl3, 75 MHz): d 18.6 (CH3),
19.3 (CH3), 21.3 (CH3), 34.2 (CH), 52.0 (CH3), 63.8 (CH),
126.9 (CH), 127.0 (CH), 128.8 (C), 129.2 (CH), 129.3
(CH), 137.4 (C), 143.0 (C), 145.2 (C), 166.7 (C]O).
Anal. Calcd for C19NSO4H23: C, 63.14; N, 3.88; S, 8.87;
H, 6.41. Found: C, 63.13; N, 3.80; S, 8.41; H, 6.48.
Treating 10 (0.157 mmol, 40 mg) according to method A
(ZnEt2, 1.5 equiv) in the presence of i-PrI (0.817 mmol,
82 mL) led after purification on silica gel (0–100% AcOEt/
pentane) to 12a (32.5 mg, 0.109 mmol, 70%) and 12b
(9.7 mg, 0.034 mmol, 22%). 1H and 13C NMR were in accor-
dance with those reported in the literature.1b
Acknowledgements
ꢁ
We thank Dr. Veronique Birault for her interest in this work.
We gratefully acknowledge GSK (UK), the CNRS and the
region PACA for the grant to F.C.
References and notes
4.2.7. 3-Methyl-2-(1-phenyl-ethylamino)-butyric acid
methyl ester (11a) and 2-(1-phenyl-ethylamino)-butyric
acid methyl ester (11b). Treating 9 (0.2 mmol, 38 mg) ac-
cording to method A (ZnEt2, 1.5 equiv) in the presence of
2a (1 mmol, 247 mg) led after purification on silica gel (0–
100% AcOEt/pentane) to 11a (40 mg, 0.17 mmol, 83%,
43:57 mixture of isomers) and 11b (4 mg, 0.018 mmol,
9%, mixture of isomers).
1. (a) Bertrand, M. P.; Feray, L.; Nouguier, R.; Perfetti, P. Synlett
1999, 1148; (b) Bertrand, M. P.; Feray, L.; Nouguier, R.;
Perfetti, P. J. Org. Chem. 1999, 64, 9189; (c) Bertrand, M. P.;
Coantic, S.; Feray, L.; Nouguier, R.; Perfetti, P. Tetrahedron
2000, 56, 3951; (d) Bertrand, M. P.; Feray, L.; Gastaldi, S. C.
R. Chimie 2002, 623.
2. (a) Yamada, K.-I.; Fujihara, H.; Yamamoto, Y.; Miwa, Y.; Taga,
T.; Tomioka, K. Org. Lett. 2002, 4, 3509; (b) Yamada, K.-I.;
Yamamoto, Y.; Maekawa, M.; Tomioka, K. J. Org. Chem.
2004, 69, 1531; (c) Yamada, K.-I.; Yamamoto, Y.; Maekawa,
M.; Chen, J.; Tomioka, K. Tetrahedron Lett. 2004, 45, 6595;
(d) Yamada, K.-I.; Yamamoto, Y.; Tomioka, K. Org. Lett.
2003, 5, 1797; (e) Yamamoto, Y.; Yamada, K.-I.; Tomioka,
K. Tetrahedron Lett. 2004, 45, 795; (f) Yamamoto, Y.;
Maekawa, M.; Akindele, T.; Yamada, K.-I.; Tomioka, K.
Tetrahedron 2005, 61, 379; (g) Yamada, K.-I.; Yamamoto, Y.;
Maekawa, M.; Akindele, T.; Umeki, H.; Tomioka, K. Org.
Lett. 2006, 8, 87; (h) Akindele, T.; Mamamoto, Y.; Maekawa,
M.; Umeki, H.; Yamada, K.-I.; Tomioka, K. Org. Lett. 2006,
8, 5729.
Treating 9 (0.2 mmol, 38 mg) according to method A
(ZnEt2, 1.5 equiv) in the presence of i-PrI (1 mmol,
100 mL) led after purification on silica gel (0–100%
AcOEt/pentane) to 11a (16.7 mg, 0.071 mmol, 36%, 43:57
mixture of isomers) and 11b (6 mg, 0.026 mmol, 13%, mix-
ture of isomers).
Treating9(0.2 mmol,38 mg)accordingtomethodC(ZnMe2,
2 equiv) in the presence of 2a (1 mmol, 247 mg) led after
purification on silica gel (0–100% AcOEt/pentane) to 11a
(35.8 mg, 0.152 mmol, 76%, 64:36 mixture of isomers).
Treating 9 (0.2 mmol, 38 mg) according to method C
(ZnMe2, 2 equiv) in the presence of 2a (0.79 mmol,
197 mg) led after purification on silica gel (0–100%
AcOEt/pentane) to 11a (41.3 mg, 0.175 mmol, 88%, 64:36
mixture of isomers).
3. (a) Miyabe, H.; Ueda, M.; Yoshioka, N.; Yamakawa, K.; Naito,
T. Tetrahedron 2000, 56, 2413; (b) Miyabe, H.; Ushiro, C.;
Ueda, M.; Yamakawa, K.; Naito, T. J. Org. Chem. 2000, 65,
176; (c) Miyabe, H.; Konishi, C.; Naito, T. Org. Lett. 2000, 2,
1443.
Treating 9 (0.2 mmol, 38 mg) according to method C
(ZnMe2, 2 equiv) in the presence of i-PrI (1 mmol,
100 mL) led after purification on silica gel (0–100%
AcOEt/pentane) to 11a (12.6 mg, 0.054 mmol, 27%, 59:41
4. For a general review on dialkylzincs in radical chemistry, see:
Bazin, S.; Feray, L.; Bertrand, M. P. Chimia 2006, 60, 260.
5. For reviews on radical addition to C]N bonds, see: (a)
Friestad, G. Tetrahedron 2001, 57, 5461; (b) Friestad, G. Eur.
J. Org. Chem. 2005, 3157.
6. Dimethylzinc was also shown to be a convenient source of
methyl radical in conjugate radical addition, see: Bazin, S.;
Feray, L.; Vanthuyne, N.; Siri, D.; Bertrand, M. P.
Tetrahedron 2007, 63, 77.
1
mixture of isomers). H and 13C NMR were in accordance
with those reported in the literature for 11a32 and 11b.1b
4.2.8. 2-(N0,N0-Diphenyl-hydrazino)-3-methyl-butyric
acid methyl ester (12a) and 2-(N0,N0-Diphenyl-